Oral Thin Films Market 2024-2033: Competitor Assessment, Industry Size And Major Players

"The new report published by The Business Research Company, titled ""Oral Thin Films Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the oral thin films market size has grown rapidly in recent years. It will grow from $4.07 billion in 2023 to $4.6 billion in 2024 at a compound annual growth rate (CAGR) of 13.0%. The oral thin films market size is expected to see rapid growth in the next few years. It will grow to $7.65 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=6067&type=smp

Rising Demand For Thin Film Drug Delivery Systems Fueling Growth In The Oral Thin Film Market
Rising demand for thin film drug delivery systems is propelling the growth of the oral thin film market. Thin films have been identified as a potential alternative to standard dosage forms. It is a convenient, self-administrable, and fast-dissolving dosage form for the delivery of medications, which makes it a versatile drug delivery platform. Thin films are taken orally and do not require water to be swallowed to absorb a drug. OTF is more patient-friendly due to its rapid dissolution rate. Due to these reasons, the demand for thin-film drug delivery systems is increasing, which is bringing more demand for oral thin films as well. For instance, in January 2021, a Turkish Journal of Pharmaceutical Sciences report shows that the global thin-film pharmaceutical products market is expected to increase from $7 billion in 2015 to over $15 billion by the end of 2024. It estimates that there will be an increase of 117% in 10 years. Thus, increasing demand for thin film drug delivery systems is driving the growth of the oral thin film market.

Increasing Focus On Product Innovations To Provide Reliable Services To Their Customers
Major companies operating in the oral thin films market are focusing on innovative products such as Rizaport to drive revenues in their market. Rizaport is a brand-name oral thin-film formulation that contains rizatriptan benzoate, an agonist of the 5-HT1 receptor and the active ingredient of Merck & Co.'s Maxalt. For instance, in September 2021, IntelGenx Technologies Corp. a Canada-based pharmaceutical company that specializes in the development of oral thin film drug delivery products launched Rizaport. Rizatriptan belongs to the class of chemicals called oral triptans that constrict blood vessels in the brain to treat migraine symptoms, including swelling, and is regarded as one of the most effective triptans. It releases its active ingredient in the tongue and dissolves quickly. Rizaport oral soluble film administration method, which does not require the patient to swallow a pill or drink water, in addition to its neutral flavor, offers a therapeutic alternative for migraine patients. This is particularly beneficial for patients with dysphagia (difficulty swallowing) and migraine-related nausea, which is thought to affect about 80% of migraine patients .

The oral thin films market covered in this report is segmented -

1) By Type: Sublingual Film, Fast Dissolving Dental/Buccal Film
2) By Disease Indication: Schizophrenia, Migraine, Opioid Dependence, Nausea & Vomiting, Other Disease Indication
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=6067&type=discount

Major companies operating in the oral thin films market include ZIM Laboratories Limited, NAL Pharma, Cure Pharmaceutical Holding Corp., IntelGenx Corp., Kyu Kyu Pharmaceutical Co. Ltd., Sunovion Pharmaceuticals Inc., Seoul Pharma Co. Ltd., Aquestive Therapeutics Inc., Shilpa Therapeutics Pvt. Ltd., Mylan Inc., LIVKON Pharmaceuticals Pvt. Ltd., Panacea Biotec Ltd., Adare Pharmaceuticals Inc., APR Applied Pharma Research SA, BioDelivery Sciences International Inc., Sumitomo Dainippon Pharma Co. Ltd., Indivior PLC, LTS Lohmann Therapie-Systeme AG, Tesa Labtec GmbH, Pfizer Inc., Sanofi S.A., Merck & Co. Inc., Novartis International AG, Roche Holding AG, Johnson & Johnson, GlaxoSmithKline plc, Bayer AG, Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, Novo Nordisk A/S, AstraZeneca plc

Contents of the report:
1. Executive Summary
2. Oral Thin Films Market Report Structure
3. Oral Thin Films Market Trends And Strategies
4. Oral Thin Films Market - Macro Economic Scenario
5. Oral Thin Films Market Size And Growth
…..
27. Oral Thin Films Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/oral-thin-films-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.